149 related articles for article (PubMed ID: 11692148)
1. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
Amirghofran Z; Monabati A; Gholijani N
Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
[TBL] [Abstract][Full Text] [Related]
3. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
4. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
5. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation.
Johnson MI; Robinson MC; Marsh C; Robson CN; Neal DE; Hamdy FC
Prostate; 1998 Dec; 37(4):223-9. PubMed ID: 9831218
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
7. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
8. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
Bubendorf L; Tapia C; Gasser TC; Casella R; Grunder B; Moch H; Mihatsch MJ; Sauter G
Hum Pathol; 1998 Sep; 29(9):949-54. PubMed ID: 9744310
[TBL] [Abstract][Full Text] [Related]
9. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.
Erbersdobler A; Fritz H; Schnöger S; Graefen M; Hammerer P; Huland H; Henke RP
Eur Urol; 2002 Jan; 41(1):40-6. PubMed ID: 11999464
[TBL] [Abstract][Full Text] [Related]
10. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.
Apakama I; Robinson MC; Walter NM; Charlton RG; Royds JA; Fuller CE; Neal DE; Hamdy FC
Br J Cancer; 1996 Oct; 74(8):1258-62. PubMed ID: 8883414
[TBL] [Abstract][Full Text] [Related]
11. Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.
Vergis R; Corbishley CM; Thomas K; Horwich A; Huddart R; Khoo V; Eeles R; Sydes MR; Cooper CS; Dearnaley D; Parker C
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):35-41. PubMed ID: 20092961
[TBL] [Abstract][Full Text] [Related]
12. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
Byrne RL; Horne CH; Robinson MC; Autzen P; Apakama I; Bishop RI; Neal DE; Hamdy FC
Br J Urol; 1997 Feb; 79(2):190-5. PubMed ID: 9052469
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.
Kallakury BV; Figge J; Ross JS; Fisher HA; Figge HL; Jennings TA
Hum Pathol; 1994 Jan; 25(1):92-7. PubMed ID: 7508886
[TBL] [Abstract][Full Text] [Related]
15. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
16. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.
Häussler O; Epstein JI; Amin MB; Heitz PU; Hailemariam S
Hum Pathol; 1999 Sep; 30(9):1077-86. PubMed ID: 10492043
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
[TBL] [Abstract][Full Text] [Related]
19. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
